# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
The total consideration of up to €275 million, consisting of an upfront cash payment of €190 million and up to €85 million in p...
Canaccord Genuity analyst Susan Anderson maintains Perrigo (NYSE:PRGO) with a Buy and maintains $42 price target.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...
Piper Sandler analyst Korinne Wolfmeyer maintains Perrigo (NYSE:PRGO) with a Overweight and raises the price target from $35...
CVS Health expands coverage to include the first OTC birth control pill in the U.S., offering accessible contraception without ...